Heat shock protein-Peptide and HSP-based immunotherapies for the treatment of cancer

Frontiers in Immunology

Volumn 7, Issue APR, 2016, Pages

  Shevtsov, Maxim ^a,b   Multhoff, Gabriele ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b INSTITUTE OF CYTOLOGY   (Russian Federation)

Author keywords

Adaptive immunity; Cancer vaccine; HSP70 heat shock proteins; HSP90 heat shock proteins; Innate immunity

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90;

AFFINITY CHROMATOGRAPHY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL (TOPIC); HUMAN; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEIN INTERACTION; SHORT SURVEY; TUMOR GROWTH; UPREGULATION; VACCINATION;

EID: 84966714463     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2016.00171     Document Type: Short Survey

References (86)

1. Srivastava PK, DeLeo AB, Old LJ. Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc Natl Acad Sci U S A (1986) 83:3407-11. doi: 10.1073/pnas.83.10.3407
2. Ullrich SJ, Robinson EA, Law LW, Willingham M, Appella E. A mouse tumor-specific transplantation antigen is a heat shock-related protein. Proc Natl Acad Sci U S A (1986) 83:3121-5. doi:10.1073/pnas.83.10.3121
3. Srivastava P. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol (2002) 20:395-425. doi:10.1146/annurev.immunol.20.100301.064801
4. Binder RJ, Han DK, Srivastava PK. CD91: a receptor for heat shock protein gp96. Nat Immunol (2000) 1:151-5. doi:10.1038/77835
5. Gong J, Zhu B, Murshid A, Adachi H, Song B, Lee A, et al. T cell activation by heat shock protein 70 vaccine requires TLR signaling and scavenger receptor expressed by endothelial cells-1. J Immunol (2009) 183:3092-8. doi:10.4049/jimmunol.0901235
6. Tosti G, Cocorocchio E, Pennacchioli E, Ferrucci PF, Testori A, Martinoli C. Heat-shock proteins-based immunotherapy for advanced melanoma in the era of target therapies and immunomodulating agents. Expert Opin Biol Ther (2014) 14:955-67. doi:10.1517/14712598.2014.902928
7. Berwin B, Hart JP, Rice S, Gass C, Pizzo SV, Post SR, et al. Scavenger receptor-A mediates gp96/GRP94 and calreticulin internalization by antigen-presenting cells. EMBO J (2003) 22:6127-36. doi:10.1093/emboj/cdg572
8. Yang Y, Liu B, Dai J, Srivastava PK, Zammit DJ, Lefrancois L, et al. Heat shock protein gp96 is a master chaperone for toll-like receptors and is important in the innate function of macrophages. Immunity (2007) 26:215-26. doi:10.1016/j.immuni.2006.12.005
9. Chalmin F, Ladoire S, Mignot G, Vincent J, Bruchard M, Remy-Martin JP, et al. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest (2010) 120:457-71. doi:10.1172/JCI40483
10. Vicencio JM, Yellon DM, Sivaraman V, Das D, Boi-Doku C, Arjun S, et al. Plasma exosomes protect the myocardium from ischemia-reperfusion injury. J Am Coll Cardiol (2015) 65:1525-36. doi:10.1016/j.jacc.2015.02.026
11. Asea A, Kraeft SK, Kurt-Jones EA, Stevenson MA, Chen LB, Finberg RW, et al. HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nat Med (2000) 6:435-42. doi:10.1038/74697
12. Vabulas RM, Ahmad-Nejad P, Ghose S, Kirschning CJ, Issels RD, Wagner H. HSP70 as endogenous stimulus of the toll/interleukin-1 receptor signal pathway. J Biol Chem (2002) 277:15107-12. doi:10.1074/jbc.M111204200
13. Becker T, Hartl FU, Wieland F. CD40, an extracellular receptor for binding and uptake of Hsp70-peptide complexes. J Cell Biol (2002) 158:1277-85. doi:10.1083/jcb.200208083
14. Botzler C, Li G, Issels RD, Multhoff G. Definition of extracellular localized epitopes of Hsp70 involved in an NK immune response. Cell Stress Chaperones (1998) 3:6-11. doi:10.1379/1466-1268(1998)003<0006:DOELEO>2.3.CO;2
15. Multhoff G, Mizzen L, Winchester CC, Milner CM, Wenk S, Eissner G, et al. Heat shock protein 70 (Hsp70) stimulates proliferation and cytolytic activity of natural killer cells. Exp Hematol (1999) 27:1627-36. doi:10.1016/S0301-472X(99)00104-6
16. Gross C, Hansch D, Gastpar R, Multhoff G. Interaction of heat shock protein 70 peptide with NK cells involves the NK receptor CD94. Biol Chem (2003) 384:267-79. doi:10.1515/BC.2003.030
17. Shevtsov MA, Pozdnyakov AV, Mikhrina AL, Yakovleva LY, Nikolaev BP, Dobrodumov AV, et al. Effective immunotherapy of rat glioblastoma with prolonged intra-tumoral delivery of exogenous heat shock protein Hsp70. Int J Cancer (2014) 135:2118-28. doi:10.1002/ijc.28858
18. Shevtsov MA, Kim AV, Samochernych KA, Romanova IV, Margulis BA, Guzhova IV, et al. Pilot study of intra-tumoral injection of recombinant heat shock protein 70 in the treatment of malignant brain tumors in children. Onco Targets Ther (2014) 7:1071-81. doi:10.2147/OTT.S62764
19. Li Z, Srivastava PK. Tumor rejection antigen gp96/grp94 is an ATPase: implications for protein folding and antigen presentation. EMBO J (1993) 12:3143-51
20. Udono H, Srivastava PK. Heat shock protein 70-associated peptides elicit specific cancer immunity. J Exp Med (1993) 178:1391-6. doi:10.1084/jem.178.4.1391
21. Udono H, Levey DL, Srivastava PK. Cellular requirements for tumor-specific immunity elicited by heat shock proteins: tumor rejection antigen gp96 primes CD8+ T cells in vivo. Proc Natl Acad Sci U S A (1994) 91:3077-81. doi:10.1073/pnas.91.8.3077
22. Srivastava PK. Purification of heat shock protein-peptide complexes for use in vaccination against cancers and intracellular pathogens. Methods (1997) 12:165-71. doi:10.1006/meth.1997.0464
23. Peng P, Menoret A, Srivastava PK. Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography. J Immunol Methods (1997) 204:13-21. doi:10.1016/S0022-1759(97)00017-3
24. Srivastava PK. Heat shock proteins in immune response to cancer: the fourth paradigm. Experientia (1994) 50:1054-60. doi:10.1007/BF01923461
25. Srivastava IK, Liu MA. Gene vaccines. Ann Intern Med (2003) 138:550-9. doi:10.7326/0003-4819-138-7-200304010-00011
26. SenGupta D, Norris PJ, Suscovich TJ, Hassan-Zahraee M, Moffett HF, Trocha A, et al. Heat shock protein-mediated cross-presentation of exogenous HIV antigen on HLA class I and class II. J Immunol (2004) 173:1987-93. doi:10.4049/jimmunol.173.3.1987
27. Blachere NE, Li Z, Chandawarkar RY, Suto R, Jaikaria NS, Basu S, et al. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. J Exp Med (1997) 186:1315-22. doi:10.1084/jem.186.8.1315
28. Belli F, Testori A, Rivoltini L, Maio M, Andreola G, Sertoli MR, et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol (2002) 20:4169-80. doi:10.1200/JCO.2002.09.134
29. Suto R, Srivastava PK. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science (1995) 269:1585-8. doi:10.1126/science.7545313
30. Noessner E, Gastpar R, Milani V, Brandl A, Hutzler PJ, Kuppner MC, et al. Tumor-derived heat shock protein 70 peptide complexes are cross-presented by human dendritic cells. J Immunol (2002) 169:5424-32. doi:10.4049/jimmunol.169.10.5424
31. Murshid A, Gong J, Calderwood SK. The role of heat shock proteins in antigen cross presentation. Front Immunol (2012) 3:63. doi:10.3389/fimmu.2012.00063
32. Binder RJ, Harris ML, Menoret A, Srivastava PK. Saturation, competition, and specificity in interaction of heat shock proteins (hsp) gp96, hsp90, and hsp70 with CD11b+ cells. J Immunol (2000) 165:2582-7. doi:10.4049/jimmunol.165.5.2582
33. Basu S, Binder RJ, Ramalingam T, Srivastava PK. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity (2001) 14:303-13. doi:10.1016/S1074-7613(01)00111-X
34. Murshid A, Theriault J, Gong J, Calderwood SK. Investigating receptors for extracellular heat shock proteins. Methods Mol Biol (2011) 787:289-302. doi:10.1007/978-1-61779-295-3_22
35. Murshid A, Borges TJ, Calderwood SK. Emerging roles for scavenger receptor SREC-I in immunity. Cytokine (2015) 75:256-60. doi:10.1016/j.cyto.2015.02.009
36. Asea A, Rehli M, Kabingu E, Boch JA, Bare O, Auron PE, et al. Novel signal transduction pathway utilized by extracellular HSP70: role of TLR2 and TLR4. J Biol Chem (2002) 277:15028-34. doi:10.1074/jbc.M200497200
37. Arnold-Schild D, Hanau D, Spehner D, Schmid C, Rammensee HG, de la SH, et al. Cutting edge: receptor-mediated endocytosis of heat shock proteins by professional antigen-presenting cells. J Immunol (1999) 162:3757-60
38. Chandawarkar RY, Wagh MS, Srivastava PK. The dual nature of specific immunological activity of tumor-derived gp96 preparations. J Exp Med (1999) 189:1437-42. doi:10.1084/jem.189.9.1437
39. Chandawarkar RY, Wagh MS, Kovalchin JT, Srivastava P. Immune modulation with high-dose heat-shock protein gp96: therapy of murine autoimmune diabetes and encephalomyelitis. Int Immunol (2004) 16:615-24. doi:10.1093/intimm/dxh063
40. Binder RJ, Zhou YJ, Messmer MN, Pawaria S. CD91-dependent modulation of immune responses by heat shock proteins: a role in autoimmunity. Autoimmune Dis (2012) 2012:863041. doi:10.1155/2012/863041
41. Oki Y, Younes A. Heat shock protein-based cancer vaccines. Expert Rev Vaccines (2004) 3:403-11. doi:10.1586/14760584.3.4.403
42. Janetzki S, Palla D, Rosenhauer V, Lochs H, Lewis JJ, Srivastava PK. Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study. Int J Cancer (2000) 88:232-8. doi:10.1002/1097-0215(20001015)88:2<232::AID-IJC14>3.0.CO;2-8
43. Srivastava PK. Therapeutic cancer vaccines. Curr Opin Immunol (2006) 18:201-5. doi:10.1016/j.coi.2006.01.009
44. Castelli C, Rivoltini L, Rini F, Belli F, Testori A, Maio M, et al. Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer. Cancer Immunol Immunother (2004) 53:227-33. doi:10.1007/s00262-003-0481-9
45. Pilla L, Patuzzo R, Rivoltini L, Maio M, Pennacchioli E, Lamaj E, et al. A Phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients. Cancer Immunol Immunother (2006) 55:958-68. doi:10.1007/s00262-005-0084-8
46. Testori A, Richards J, Whitman E, Mann GB, Lutzky J, Camacho L, et al. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol (2008) 26:955-62. doi:10.1200/JCO.2007.11.9941
47. Schadendorf D, Ugurel S, Schuler-Thurner B, Nestle FO, Enk A, Brocker EB, et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized Phase III trial of the DC study group of the DeCOG. Ann Oncol (2006) 17:563-70. doi:10.1093/annonc/mdj138
48. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med (1998) 4:328-32. doi:10.1038/nm0398-328
49. Mazzaferro V, Coppa J, Carrabba MG, Rivoltini L, Schiavo M, Regalia E, et al. Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin Cancer Res (2003) 9:3235-45
50. Wood C. A vaccine for renal cancer. Lancet (2008) 372:1460-1. doi:10.1016/S0140-6736(08)61615-3
51. Hertkorn C, Lehr A, Wölfel T, Junginger T, Dippold WG, Galle PR, et al. Phase I trial of vaccination with autologous tumor-derived gp96 in patients after surgery for gastric cancer. Proc Am Soc Clin Oncol (2002) 21:30a
52. Heike M, Hertkorn C, Reitsma DJ, Kommoss F, Simiantonaki N, Woelfel T, et al. Pilot trial of vaccination with autologous tumor-derived GP96 heat shock protein-peptide complex (HSPPC-96) in patients after surgery for gastric carcinoma. Proc Am Soc Clin Oncol (2000) 19:1825
53. Maki RG, Livingston PO, Lewis JJ, Janetzki S, Klimstra D, Desantis D, et al. A Phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma. Dig Dis Sci (2007) 52:1964-72. doi:10.1007/s10620-006-9205-2
54. Hammond DB. What ASCO does for its members. J Clin Oncol (2004) 22:2251-2. doi:10.1200/JCO.2004.99.075
55. Bloch O, Crane CA, Fuks Y, Kaur R, Aghi MK, Berger MS, et al. Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a Phase II, single-arm trial. Neuro Oncol (2014) 16:274-9. doi:10.1093/neuonc/not203
56. Gehrmann M, Schmetzer H, Eissner G, Haferlach T, Hiddemann W, Multhoff G. Membrane-bound heat shock protein 70 (Hsp70) in acute myeloid leukemia: a tumor specific recognition structure for the cytolytic activity of autologous NK cells. Haematologica (2003) 88:474-6
57. Multhoff G, Botzler C, Jennen L, Schmidt J, Ellwart J, Issels R. Heat shock protein 72 on tumor cells: a recognition structure for natural killer cells. J Immunol (1997) 158:4341-50
58. Multhoff G, Botzler C, Wiesnet M, Muller E, Meier T, Wilmanns W, et al. A stress-inducible 72-kDa heat-shock protein (HSP72) is expressed on the surface of human tumor cells, but not on normal cells. Int J Cancer (1995) 61:272-9. doi:10.1002/ijc.2910610222
59. Shin BK, Wang H, Yim AM, Le Naour F, Brichory F, Jang JH, et al. Global profiling of the cell surface proteome of cancer cells uncovers an abundance of proteins with chaperone function. J Biol Chem (2003) 278:7607-16. doi:10.1074/jbc.M210455200
60. Stangl S, Gehrmann M, Riegger J, Kuhs K, Riederer I, Sievert W, et al. Targeting membrane heat-shock protein 70 (Hsp70) on tumors by cmHsp70.1 antibody. Proc Natl Acad Sci U S A (2011) 108:733-8. doi:10.1073/pnas.1016065108
61. Breuninger S, Erl J, Knape C, Gunther S, Regel I, Rodel F, et al. Quantitative analysis of liposomal heat shock protein 70 (Hsp70) in the blood of tumor patients using an novel lipHsp70 ELISA. J Clin Cell Immunol (2014) 5:2-10. doi:10.4172/2155-9899.1000264
62. Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones (2005) 10:86-103. doi:10.1379/CSC-99r.1
63. Gastpar R, Gehrmann M, Bausero MA, Asea A, Gross C, Schroeder JA, et al. Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells. Cancer Res (2005) 65:5238-47. doi:10.1158/0008-5472.CAN-04-3804
64. Murakami N, Kuhnel A, Schmid TE, Ilicic K, Stangl S, Braun IS, et al. Role of membrane Hsp70 in radiation sensitivity of tumor cells. Radiat Oncol (2015) 10:149. doi:10.1186/s13014-015-0461-1
65. Multhoff G, Pfister K, Gehrmann M, Hantschel M, Gross C, Hafner M, et al. A 14-mer Hsp70 peptide stimulates natural killer (NK) cell activity. Cell Stress Chaperones (2001) 6:337-44. doi:10.1379/1466-1268(2001)006<0337:AMHPSN>2.0.CO;2
66. Biassoni R. Human natural killer receptors, co-receptors, and their ligands. Curr Protoc Immunol (2009) Chapter 14:Unit14.10. doi:10.1002/0471142735.im1410s84
67. Pegram HJ, Andrews DM, Smyth MJ, Darcy PK, Kershaw MH. Activating and inhibitory receptors of natural killer cells. Immunol Cell Biol (2011) 89:216-24. doi:10.1038/icb.2010.78
68. Sullivan LC, Clements CS, Beddoe T, Johnson D, Hoare HL, Lin J, et al. The heterodimeric assembly of the CD94-NKG2 receptor family and implications for human leukocyte antigen-E recognition. Immunity (2007) 27:900-11. doi:10.1016/j.immuni.2007.10.013
69. Borrego F, Masilamani M, Marusina AI, Tang X, Coligan JE. The CD94/NKG2 family of receptors: from molecules and cells to clinical relevance. Immunol Res (2006) 35:263-78. doi:10.1385/IR:35:3:263
70. Gross C, Schmidt-Wolf IG, Nagaraj S, Gastpar R, Ellwart J, Kunz-Schughart LA, et al. Heat shock protein 70-reactivity is associated with increased cell surface density of CD94/CD56 on primary natural killer cells. Cell Stress Chaperones (2003) 8:348-60. doi:10.1379/1466-1268(2003)008<0348:HSPRIA>2.0.CO;2
71. Gross C, Koelch W, DeMaio A, Arispe N, Multhoff G. Cell surface-bound heat shock protein 70 (Hsp70) mediates perforin-independent apoptosis by specific binding and uptake of granzyme B. J Biol Chem (2003) 278:41173-81. doi:10.1074/jbc.M302644200
72. Krause SW, Gastpar R, Andreesen R, Gross C, Ullrich H, Thonigs G, et al. Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical Phase I trial. Clin Cancer Res (2004) 10:3699-707. doi:10.1158/1078-0432.CCR-03-0683
73. Specht HM, Ahrens N, Blankenstein C, Duell T, Fietkau R, Gaipl US, et al. Heat shock protein 70 (Hsp70) peptide activated natural killer (NK) cells for the treatment of patients with non-small cell lung cancer (NSCLC) after radiochemotherapy (RCTx)-from preclinical studies to a clinical Phase II trial. Front Immunol (2015) 6:162. doi:10.3389/fimmu.2015.00162
74. Elsner L, Muppala V, Gehrmann M, Lozano J, Malzahn D, Bickeboller H, et al. The heat shock protein Hsp70 promotes mouse NK cell activity against tumors that express inducible NKG2D ligands. J Immunol (2007) 179:5523-33. doi:10.4049/jimmunol.179.8.5523
75. Takemoto S, Nishikawa M, Guan X, Ohno Y, Yata T, Takakura Y. Enhanced generation of cytotoxic T lymphocytes by heat shock protein 70 fusion proteins harboring both CD8(+) T cell and CD4(+) T cell epitopes. Mol Pharm (2010) 7:1715-23. doi:10.1021/mp1001069
76. Guzhova IV, Shevtsov MA, Abkin SV, Pankratova KM, Margulis BA. Intracellular and extracellular Hsp70 chaperone as a target for cancer therapy. Int J Hyperthermia (2013) 29:399-408. doi:10.3109/02656736.2013.807439
77. Asea A. Initiation of the immune response by extracellular Hsp72: chaperokine activity of Hsp72. Curr Immunol Rev (2006) 2:209-15. doi:10.2174/157339506778018514
78. Geng H, Zhang GM, Xiao H, Yuan Y, Li D, Zhang H, et al. HSP70 vaccine in combination with gene therapy with plasmid DNA encoding sPD-1 overcomes immune resistance and suppresses the progression of pulmonary metastatic melanoma. Int J Cancer (2006) 118:2657-64. doi:10.1002/ijc.21795
79. Rafiee M, Kanwar JR, Berg RW, Lehnert K, Lisowska K, Krissansen GW. Induction of systemic anti-tumor immunity by gene transfer of mammalian heat shock protein 70.1 into tumors in situ. Cancer Gene Ther (2001) 8:974-81. doi:10.1038/sj.cgt.7700395
80. Nishikawa M, Otsuki T, Ota A, Guan X, Takemoto S, Takahashi Y, et al. Induction of tumor-specific immune response by gene transfer of Hsp70-cell-penetrating peptide fusion protein to tumors in mice. Mol Ther (2010) 18:421-8. doi:10.1038/mt.2009.203
81. Ito A, Matsuoka F, Honda H, Kobayashi T. Anti-tumor effects of combined therapy of recombinant heat shock protein 70 and hyperthermia using magnetic nanoparticles in an experimental subcutaneous murine melanoma. Cancer Immunol Immunother (2004) 53:26-32. doi:10.1007/s00262-003-0416-5
82. Shevtsov MA, Komarova EY, Meshalkina DA, Bychkova NV, Aksenov ND, Abkin SV, et al. Exogenously delivered heat shock protein 70 displaces its endogenous analogue and sensitizes cancer cells to lymphocytes-mediated cytotoxicity. Oncotarget (2014) 5:3101-14. doi:10.18632/oncotarget.1820
83. Shevtsov MA, Nikolaev BP, Yakovleva LY, Parr MA, Marchenko YY, Eliseev I, et al. 70-kDa heat shock protein coated magnetic nanocarriers as a nanovaccine for induction of anti-tumor immune response in experimental glioma. J Control Release (2015) 220:329-40. doi:10.1016/j.jconrel.2015.10.051
84. Li JL, Liu HL, Zhang XR, Xu JP, Hu WK, Liang M, et al. A Phase I trial of intra-tumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients. Gene Ther (2009) 16:376-82. doi:10.1038/gt.2008.179
85. Maeda Y, Yoshimura K, Matsui H, Shindo Y, Tamesa T, Tokumitsu Y, et al. Dendritic cells transfected with heat-shock protein 70 messenger RNA for patients with hepatitis C virus-related hepatocellular carcinoma: a Phase I dose escalation clinical trial. Cancer Immunol Immunother (2015) 64:1047-56. doi:10.1007/s00262-015-1709-1
86. Schildkopf P, Frey B, Ott OJ, Rubner Y, Multhoff G, Sauer R, et al. Radiation combined with hyperthermia induces Hsp70-dependent maturation of dendritic cells and release of pro-inflammatory cytokines by dendritic cells and macrophages. Radiother Oncol (2011) 101:109-15. doi:10.1016/j.radonc.2011.05.056